GlassScriptPhysician profile
Kaio Ferreira
NPI 1689103293
$2,611.99
in general payments reported to CMS, 2019-2025
20 companies · $1,016 in 2025
The $1,016 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $34.67 · 2021: $407 · 2022: $369 · 2023: $223 · 2024: $563 · 2025: $1,016.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,723 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,722.58 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $670.34 | 2024-2025 | |
| Janssen Biotech, INC. | $328.97 | 2020-2025 | Stelara, Tremfya |
| Medtronic, INC. | $292.78 | 2021-2024 | Bravo |
| Janssen Scientific Affairs, LLC | $255.10 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $231.45 | 2024-2025 | Entyvio, Eohilia |
| Boston Scientific Corporation | $220.03 | 2021-2022 | |
| Genzyme Corporation | $106.47 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $95.23 | 2023-2025 | Dupixent |
| Madrigal Pharmaceuticals | $73.11 | 2025 | Rezdiffra |
| Lilly USA, LLC | $70.93 | 2023-2025 | Omvoh |
| Daiichi Sankyo INC. | $56.32 | 2024 | Injectafer |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.56 | 2023-2024 | Xifaxan |
| Celgene Corporation | $38.83 | 2023-2024 | Zeposia |
| Ardelyx, INC. | $26.94 | 2024 | Ibsrela |
| Qol Medical, LLC | $26.94 | 2024 | Sucraid |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $20.19 | 2024 | Zinplava, Dificid |
| Thd America, INC. | $16.05 | 2025 | |
| Capsovision, INC. | $15.39 | 2024 | Capsocam Plus |
| Novo Nordisk INC | $14.91 | 2025 | Wegovy |
| Micro-Tech Endoscopy USA, INC. | $12.45 | 2024 | Lesionhunter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaio Ferreira listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.